BioXcel Therapeutics (BTAI) Net Equity Issued and Repurchased (2017 - 2026)

BioXcel Therapeutics' Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $8.5 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased fell 39.33% year-over-year to $8.5 million in Q1 2026; TTM through Mar 2026 was $52.6 million, a 120.7% increase from a year earlier, with the FY2025 full-year figure at $58.1 million, up 46.5% from the prior year.
• Net Equity Issued and Repurchased climbed to $8.5 million in Q1 2026 per BTAI's latest filing, from $5.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $38.2 million in Q3 2025 and bottomed at $140000.0 in Q2 2025.
• The 4-year median for Net Equity Issued and Repurchased is $7.0 million (2024), against an average of $11.2 million.
• Across the five-year window, Net Equity Issued and Repurchased soared 8087.15% in 2025 and plunged 39.33% in 2026, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $2.4 million in 2023, then jumped by 194.78% to $7.0 million in 2024, then fell by 17.7% to $5.8 million in 2025, then surged by 47.48% to $8.5 million in 2026.
• Per Business Quant, the three latest BTAI Net Equity Issued and Repurchased figures stand at $8.5 million (Q1 2026), $5.8 million (Q4 2025), and $38.2 million (Q3 2025).